Atrioventricular Interval Modulation Therapy (AVIM Therapy) has demonstrated promising results in the MODERATO II trial, showing an immediate average reduction of 13.2 mmHg in office systolic blood pressure (oSBP). Notably, 97% of patients experienced a reduction of more than 5 mmHg prior to randomization. This innovative therapy, designed for patients with hypertensive heart disease, not only delivered significant blood pressure reductions but also indicated improvements in diastolic function and reverse cardiac remodeling. These findings were presented at the Heart Rhythm Society (HRS) 2026 Annual Meeting, highlighting the potential of AVIM Therapy to provide immediate and sustained blood pressure control without the need for additional medications.

The clinical implications of these results are substantial, particularly for the older, higher-risk patient population that often struggles with uncontrolled hypertension despite existing medical therapies. At six months post-therapy, the mean ambulatory systolic blood pressure (aSBP) was 125.2 mmHg, with 89% of patients achieving aSBP below the European Society of Cardiology’s target of 140 mmHg. Furthermore, 58% reached the more stringent U.S. goal of 130 mmHg. These outcomes suggest that AVIM Therapy could redefine treatment paradigms for hypertension, particularly in patients who are pacemaker candidates, by offering a bioelectronic solution that enhances patient adherence and outcomes.

The ongoing BACKBEAT Global Pivotal Trial aims to further validate these findings and assess the long-term efficacy and safety of AVIM Therapy. If successful, this could accelerate the integration of bioelectronic therapies into standard hypertension management, potentially shortening drug development timelines and reshaping therapeutic strategies for hypertension in aging populations. The collaboration with Medtronic underscores the strategic importance of AVIM Therapy in addressing a significant global health challenge.

Source: globenewswire.com